

References

I-171

1. Micromedex DrugDex Compendium®. 2024. Ocrelizumab.
2. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Ocrelizumab.
3. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. *N Engl J Med*. 2017;209-20.
4. Ocrevus (Ocrelizumab) injection, for intravenous use [package insert]. Genentech, Inc. South San Francisco, CA. Revised 01/2024.
5. Gelfand J, Cree B, & Hauser S. Ocrelizumab and other CD20+ b-cell-depleting therapies in multiple sclerosis. *Neurotherapeutics*. 2017;14:835-841.
6. MCGTM Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
7. Soelberg Sorensen P. Safety concerns and risk management of multiple sclerosis therapies. *Acta Neurologica Scandinavica*. 2017;136(3):168-186.
8. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *The Lancet*. 2018. 17(2):162-173.
9. Daniels K, van der Nat PB, Frequin STFM, et al. Real-world results of ocrelizumab treatment for primary progressive multiple sclerosis. *Multiple Sclerosis International*.2020:1-6.
10. Dirks P, Zingler V, Leemhuis J, et al. Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol. *BMC Neurology*. 2020;20(1):1-9.
11. Ocrelizumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated December 17, 2022.
12. Hauser SL, Kappos L, Arnold DL, et al. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. *Neurology*. 2020;95(13):e1854-e1867.
13. Hughes R, Whitley L, Fitovski K, et al. COVID-19 in ocrelizumab-treated people with multiple sclerosis. *Mult Scler Relat Disord*. 2021;49:102725. doi: 10.1016/j.msard.2020.102725.
14. Ocrevus Zunovo™ (ocrelizumab and hyaluronidase-ocsq) injection, for subcutaneous use [package insert]. Genentech, Inc. South San Francisco, CA. Revised 09/2024.
15. Newsome S, Krzystanek E, Selmaj K, et al. OCARINA II, Phase III Study: Results of Subcutaneous Ocrelizumab Administration in Patients with Multiple Sclerosis. *Neurology*. 2024;102(17).